Cullinan Oncology hires Jeffrey Jones as CMO and appoints Anne-Marie Martin to board

Cullinan Therapeutics, Inc.

Jeffrey Jones, M.D., MPH, MBA, appointed CMO effective Feb 28, 2022; previously VP at Bristol Myers Squibb.
Annual base salary $460,000; sign-on bonus $100,000; option for 215,000 shares at $14.34.
Dr. Jones' option vests 25% on first anniversary, remainder monthly over three years.
Anne-Marie Martin, Ph.D., appointed Class I director effective Mar 1, 2022; SVP at GlaxoSmithKline.
Dr. Martin received option grant with grant-date fair value $350,000 vesting over three years.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey Jones

Chief Medical Officer

CGEM · Cullinan Therapeutics, Inc.

Effective: 2022-02-28
Filed: March 3, 2022, 6:59 PM ET

On February 28, 2022, Cullinan Oncology, Inc. (the “Company”) announced the hiring and appointment of Jeffrey Jones, M.D., MPH, MBA as the Company’s Chief Medical Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Jones was appointed as Chief Medical Officer at Cullinan Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On February 28, 2022, Cullinan Oncology, Inc. (the “Company”) announced the hiring and appointment of Jeffrey Jones, M.D., MPH, MBA as the Company’s Chief Medical Officer, effective immediately.

View on SEC.gov

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-063699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.